|
1
|
American Cancer Society. Cancer Facts
& Figures. 2018.
|
|
2
|
Cancer Prevention Group: Annual Report of
Taiwan Cancer Registry for 2016. December 27–2018, https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227
|
|
3
|
Huang CY, Lin YC, Shiue HS, Chen WJ, Su
CT, Pu YS, Ao PL and Hsueh YM: Comparison of arsenic methylation
capacity and polymorphisms of arsenic methylation genes between
bladder cancer and upper tract urothelial carcinoma. Toxicol Lett.
295:64–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boulanger M, Tual S, Lemarchand C, Guizard
AV, Velten M, Marcotullio E, Baldi I, Clin B and Lebailly PP:
Agricultural exposure and risk of bladder cancer in the AGRIculture
and CANcer cohort. Int Arch Occup Environ Health. 90:169–178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mendez WM Jr, Eftim S, Cohen J, Warren I,
Cowden J, Lee JS and Sams R: Relationships between arsenic
concentrations in drinking water and lung and bladder cancer
incidence in U.S. counties. J Expo Sci Environ Epidemiol.
27:235–243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shibata A, Ohneseit PF, Tsai YC, Spruck CH
III, Nichols PW, Chiang HS, Lai MK and Jones PA: Mutational
spectrum in the p53 gene in bladder tumors from the endemic area of
black foot disease in Taiwan. Carcinogenesis. 15:1085–1087. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
NNational Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology (NCCN GuidelinesÒ).
Bladder cancer Version 2.2018. February 7–2018.https://oncolife.com.ua/doc/nccn/Bladder_Cancer.pdf
|
|
8
|
Shelley MD, Mason MD and Kynaston H:
Intravesical therapy for superficial bladder cancer: A systematic
review of randomised trials and meta-analyses. Cancer Treat Rev.
36:195–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koga F, Takemura K and Fukushima H:
Biomarkers for predicting clinical outcomes of chemoradiation-based
bladder preservation therapy for muscle-invasive bladder cancer.
Int J Mol Sci. 19:E27772018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rauf A, Patel S, Imran M, Maalik A, Arshad
MU, Saeed F, Mabkhot YN, Al-Showiman SS, Ahmad N and Elsharkawy E:
Honokiol: An anticancer lignan. Biomed Pharmacother. 107:555–562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zubair H, Azim S, Ahmad A, Khan MA, Patel
GK, Singh S and Singh AP: Cancer chemoprevention by phytochemicals:
Nature's healing touch. Molecules. 22:E3952017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee YJ, Lee YM, Lee CK, Jung JK, Han SB
and Hong JT: Therapeutic applications of compounds in the magnolia
family. Pharmacol Ther. 130:157–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumar A, Kumar Singh U and Chaudhary A:
Honokiol analogs: A novel class of anticancer agents targeting cell
signaling pathways and other bioactivities. Future Med Chem.
5:809–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prasad R and Katiyar SK: Honokiol, an
active compound of Magnolia plant, inhibits growth, and progression
of cancers of different organs. Adv Exp Med Biol. 928:245–265.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chio CC, Chen KY, Chang CK, Chuang JY, Liu
CC, Liu SH and Chen RM: Improved effects of honokiol on
temozolomide-induced autophagy and apoptosis of drug-sensitive and
-tolerant glioma cells. BMC Cancer. 18:3792018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chio CC, Tai YT, Mohanraj M, Liu SH, Yang
ST and Chen RM: Honokiol enhances temozolomide-induced apoptotic
insults to malignant glioma cells via an intrinsic
mitochondrion-dependent pathway. Phytomedicine. 49:41–51. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai IC, Shih PH, Yao CJ, Yeh CT,
Whang-Peng J, Lui TN, Chuang SE, Hu TS, Lai TY and Lai GM:
Elimination of cancer stem-like cells and potentiation of
temozolomide sensitivity by Honokiol in glioblastoma multiforme
cells. PLoS One. 10:e01148302015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang MT, Lee SP, Fang CY, Hsieh PL, Liao
YW, Lu MY, Tsai LL, Yu CC and Liu CM: Chemosensitizing effect of
honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3
signaling. Environ Toxicol. 33:1105–1112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Q, Zhao W, Ye C, Zhuang J, Chang C,
Li Y, Huang X, Shen L, Li Y, Cui Y, et al: Honokiol inhibits
bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget.
6:37335–37348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen L, Zhang F, Huang R, Yan J and Shen
B: Honokiol inhibits bladder cancer cell invasion through
repressing SRC-3 expression and epithelial-mesenchymal transition.
Oncol Lett. 14:4294–4300. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Monappa V, Reddy SM and Kudva R:
Hematolymphoid neoplasms in effusion cytology. Cytojournal.
15:152018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Danova M, Torchio M, Comolli G, Sbrana A,
Antonuzzo A and Mazzini G: The role of automated cytometry in the
new era of cancer immunotherapy. Mol Clin Oncol. 9:355–361.
2018.PubMed/NCBI
|
|
24
|
Li CG, Ni CL, Yang M, Tang YZ, Li Z, Zhu
YJ, Jiang ZH, Sun B and Li CJ: Honokiol protects pancreatic beta
cell against high glucose and intermittent hypoxia-induced injury
by activating Nrf2/ARE pathway in vitro and in vivo. Biomed
Pharmacother. 97:1229–1237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Liao Z, Sun X, Shi Q, Huo G, Xie
Y, Tang X, Zhi X and Tang Z: Intravenous administration of Honokiol
provides neuroprotection and improves functional recovery after
traumatic brain injury through cell cycle inhibition.
Neuropharmacology. 86:9–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu JX, Shen SN, Tong Q, Wang YT and Lin
LG: Honokiol protects hepatocytes from oxidative injury through
mitochondrial deacetylase SIRT3. Eur J Pharmacol. 834:176–187.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Halasi M, Hitchinson B, Shah BN, Váraljai
R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL and Gartel
AL: Honokiol is a FOXM1 antagonist. Cell Death Dis. 9:842018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Green DR and Llambi F: Cell death
signaling. Cold Spring Harb Perspect Biol. 7:a0060802015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hua H, Chen W, Shen L, Sheng Q and Teng L:
Honokiol augments the anti-cancer effects of oxaliplatin in colon
cancer cells. Acta Biochim Biophys Sin (Shanghai). 45:773–779.
2013. View Article : Google Scholar : PubMed/NCBI
|
